Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COURAGE: CHT101 in Hematological Malignancies
NCT06914037Phase 1Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CHT101 in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), aggressive B-cell lymphoma and 2 more, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Dose-limiting toxicity at 28 days and Maximum tolerated dose at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
CHT101
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)aggressive B-cell lymphomaindolent B-cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06914037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914037.